



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 15 Oct 2019 (#34)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices & News

- Consolidated Notice on NCCIH Clinical Trials Policies [NOT-AT-20-001](#)
- Guidance on Posting Informed Consent Forms for AHRQ-Funded Clinical Trials [NOT-HS-19-023](#)
- Notice of Intent to Publish a Funding Opportunity Announcement for Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional) [NOT-GM-19-061](#) The FOA is intended for new applications from [early stage investigators](#) The FOA is expected to be published in early 2020 with an expected first application due date in October 2020. NIGMS intends to: 1) encourage eligible applicants to apply earlier in their independent research career; 2) enhance applicants' ability to move into research areas that are distinct from those of their postdoctoral mentors; and 3) emphasize that preliminary data are neither required nor expected. Review criteria will be revised accordingly, and reviewers will be oriented to these new FOA goals.
- Pre-Solicitation Notice: Preclinical Services for HIV Therapeutics, RFP: 75N93019R00021 [NOT-AI-20-002](#) The NIAID supports resources and services to assist academic, small business and other investigators, including contracts that provide or make available research materials, in vitro drug screening, chemical synthesis including small scale Good Manufacturing Practice (GMP) synthesis, small animal efficacy models, drug formulation, preclinical pharmacology and toxicology, and other discovery and preclinical services to aid the advancement of promising agents from bench to clinics. Over the past years, these contract activities have helped investigators to obtain critical data and materials to attract additional funding, gain prospective partnership, fulfill regulatory requirements, and complete studies before entering clinical trials. Information about these contract resources or activities can be found at the following website: <https://www.niaid.nih.gov/research/resources> The purpose of the proposed Indefinite Delivery/Indefinite Quantity contracts is to provide the extramural scientific community with research materials and preclinical product development support for candidate products that emerge from investigator-initiated research studies or from collaborations with private sector or academic partners. The scope of work encompasses activities that range from basic research and initial product discovery to activities required for clinical trials and/or product licensure. These services may also be used to support product discovery and development leading to Investigational New Drug Application (IND), Investigational Device Exemption (IDE), and/or New Drug Application (NDA) filings with the Food and Drug Administration (FDA). NIAID will primarily use these contracts to fill critical development and resource gaps more rapidly and efficiently and advance promising products into clinical testing. Although the focus of these contracts will be development of therapeutic products for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Mycobacterium tuberculosis (MTB) complex, as well as repository services, at the discretion of NIAID, these contracts may also be used to advance vaccines, antivirals, and preventive strategies for these and other infectious diseases.
- Notice of Special Interest (NOSI): Use of Biological Information to Understand How the Interplay of Environmental Exposures and Genes Influences Cancer Risk [NOT-CA-20-002](#) The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants to the National Cancer Institute (NCI) of special interest to promote research that incorporates biological information within population-based cancer epidemiologic studies to identify and understand how the interplay between environmental exposures (e.g., chemical and physical exposures, dietary, and other exposures) and germline genetic variation contribute to cancer risk. Biological information can include functional annotations of the genome (e.g., methylation, promoters or enhancers); methods of linking variants to genes (e.g., expression quantitative trait loci analysis), gene pathway or network-based approaches (e.g., network modeling); analysis of metabolites or biomarkers, or data from mechanistic studies.
- Notice of Special Interest: Research on Emergency Medical Services for Children (EMSC) [NOT-HD-19-022](#) Unintentional injury is the leading cause of death for individuals from ages 1 to 44 years. Emergency care for Infants and children differs from care for adults in terms of medication doses, resuscitation equipment, procedural techniques, and psychological support. Research is needed to improve the quality and quantity of research related to emergency medical services for children (EMSC) with the

goal of reducing morbidity and mortality in children through improved care delivery. Improvements in pre-hospital care, emergency department care, and in-hospital critical care are needed to reduce pediatric deaths and disability, and to improve long-term recovery.

- **Notice of Special Interest: Understanding the biology of iodine nutrition, assessment, and outcomes in women, infants, and children (R01, R21, R03) [NOT-HD-19-028](#)** Iodine is an essential nutrient that must be obtained via the food supply in order to meet established requirements for health. Despite a long and evolving history of understanding with regard to the impact of iodine deficiency, meeting iodine requirements remains a domestic and global challenge. Because of its key role in human development, adequate iodine nutrition of women of reproductive age, during pregnancy, and infancy is a critical public health priority. Despite significant progress in terms of public health programs and interventions, significant gaps remain to be filled in order to fully inform these efforts, particularly with regard to our understanding of the biology, assessment, and outcomes of iodine status in these vulnerable groups. This Notice will encourage research using a range of disciplines and approaches to address the gaps in our understanding of the biology and functional impact of iodine nutrition, and in particular, mild-to-moderate iodine deficiency in women of reproductive age (including during adolescence, pregnancy, and lactation) as well as in infants and children.
- **Notice of Special Interest (NOSI): Epidemiologic Studies to Characterize Cardiovascular Health and its Predictors and Trajectories in Diverse Groups of Children [NOT-HL-19-711](#)** The purpose of this initiative is to stimulate and support novel epidemiological research that assesses cardiovascular health, its trajectory during childhood and its relationship to adult disease. Currently there is evidence that CVD starts early in life, however metrics for ideal cardiovascular health (ICVH) during key pediatric developmental periods is limited. This critical information is severely limited or absent particularly in underrepresented populations. This initiative will help to define those metrics and lay a foundation to support integration of clinical, population, and mechanistic behavioral studies to provide early information on the predictors of CVH. Such information could inform the design of interventions that would preserve or promote optimal cardiovascular health in the pediatric population. Research supported by this initiative will leverage existing resources, address disparities in cardiovascular health and enhance the careers of early stage investigators by supporting focused analytic and ancillary study collaborative opportunities.

**1. Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-20-029](#)

**Type:** R01

**Application Due Date:** Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** January 7, 2020; January 7, 2021; January 7, 2022. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention. Applications may propose treatment or prevention products delivered using sustained release platforms (oral, injection, implant or direct delivery to HIV target mucosa) that will provide a minimum of 1 week for oral (treatment) or a minimum of once a month for all other drug delivery systems for prevention and treatment.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**2. Small Research Grant Program for the Next Generation of Clinical Researchers in AD/ADRD Research: Area of Focus Archiving and Leveraging Existing Data Sets for Analyses (Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAS-19-391](#)

**Type:** R03

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Small Research Grant (R03) will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.

**Budget:** NIH intends to fund an estimated 12 awards for this FOA and its companions, corresponding to a total of \$1.8 million, for fiscal year 2020. Future year amounts will depend on annual appropriations. Applications may request budgets of up to \$100,000 in direct costs per year for up to two years. The scope of the project should determine the project period. The maximum project period is 2 years.

**3. Understanding Phage Biology to Support the Development of Bacteriophage Therapy (Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-19-065](#)

**Type:** R21

**Application Due Date:** March 18, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This initiative will support basic and translational research to address knowledge gaps that hinder the development and regulation of bacteriophage used to prevent and treat drug-resistant bacterial infections.

**Budget:** NIAID intends to commit \$2.5 million in FY 2021 to fund 6-8 awards. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

**4. Small Research Grant Program for the Next Generation of Clinical Researchers in AD/ADRD Research: Area of Focus Basic Science (Clinical Trials Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAS-19-392](#)

**Type:** R03

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.

**Budget:** NIH intends to fund an estimated 12 awards for this FOA and its companions, corresponding to a total of \$1.8 million, for fiscal year 2020. Future year amounts will depend on annual appropriations. Applications may request budgets of up to \$100,000 in direct costs per year for up to two years.

**5. Small Research Grant Program for the Next Generation of Clinical Researchers in AD/ADRD Research: Area of Focus Systems Biology (Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAS-19-393](#)

**Type:** R03

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Small Research Grant Program (R03) will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.

**Budget:** NIH intends to fund an estimated 12 awards for this FOA and its companions, corresponding to a total of \$1.8 million, for fiscal year 2020. Future year amounts will depend on annual appropriations. Applications may request budgets of up to \$100,000 in direct costs per year for up to two years.

**6. Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-19-059](#)

**Type:** U01

**Application Due Date:** January 17, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this initiative is to stimulate basic research, discovery, and early translational research to enable and accelerate the generation of highly efficacious pre-erythrocytic stage malaria vaccines, including sporozoite-based vaccines. Cross-fertilization and collaboration among investigators from malaria vaccine research and other basic research areas such as parasite biology, parasite genomics, pathogenesis, and host immunology are highly encouraged. The goal is to generate one or more promising vaccine candidates against human malaria that exhibit performance superior to currently available sporozoite-based vaccines and are suitable for further downstream process development and future clinical evaluation.

**Budget:** NIAID intends to commit \$6M in FY 2021 to fund 4-6 awards. The application budget may not exceed \$750K in direct costs per year and should reflect the actual needs of the project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105